An update on multipurpose prevention technologies for the prevention of HIV transmission and pregnancy

References

• Friend DR. Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission. Expert Opin Drug Deliv. 2012;9:417–427. doi:10.1517/17425247.2012.668183.
   PubMed Web of Science ®Google Scholar
• Thurman AR, Clark MR, Doncel GF. Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol. 2011;2011:1–10. doi:10.1155/2011/429403.
   PubMedGoogle Scholar
• Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England J Med. 2015;372:509–518. doi:10.1056/NEJMoa1402269.
   PubMed Web of Science ®Google Scholar
• Rees H, Delany-Moretlwe S, Lombard C, et al. FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. Conference on Retroviruses and Opportunistic Infections; Seattle, WA; 2015. p. 26LB.
   Google Scholar
• Malcolm RK, Fetherston SM. Delivering on MPTs: addressing the needs, rising to the challenges and making the opportunities. Contraception. 2013;88:321–325. doi:10.1016/j.contraception.2013.06.009.
   PubMed Web of Science ®Google Scholar
• Malcolm RK, Boyd P, McCoy CF, et al. Beyond HIV microbicides: multipurpose prevention technology products. BJOG: Int J Obstetrics Gynaecol. 2014;121:62–69. doi:10.1111/1471-0528.12852.
   PubMed Web of Science ®Google Scholar
• Fernández-Romero JA, Deal C, Herold BC, et al. Multipurpose prevention technologies: the future of HIV and STI protection. Trends Microbiol. 2015;23:429–436.
   PubMed Web of Science ®Google Scholar
• Romano JW, Van Damme L, Hillier S. The future of multipurpose prevention technology product strategies: understanding the market in parallel with product development. BJOG: Int J Obstetrics Gynaecol. 2014;121:15–18.
   PubMed Web of Science ®Google Scholar
• Abdool Karim S, Baxter C, Frohlich J, et al. The need for multipurpose prevention technologies in sub-Saharan Africa. BJOG: Int J Obstetrics Gynaecol. 2014;121:27–34.
   PubMed Web of Science ®Google Scholar
• Zheng N, Guo Y, Padmadas S, et al. The increase of sexually transmitted infections calls for simultaneous preventive intervention for more effectively containing HIV epidemics in China. BJOG: Int J Obstetrics Gynaecol. 2014;121:35–44. doi:10.1111/1471-0528.12999.
   PubMed Web of Science ®Google Scholar
• Woodsong C, Holt JD. Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy. Adv Drug Deliv Rev. 2015;19:146–154.
   Google Scholar
• Brady M, Tolley E. Aligning product development and user perspectives: social–behavioural dimensions of multipurpose prevention technologies. BJOG: Int J Obstetrics Gynaecol. 2014;121:70–78. doi:10.1111/bjo.2014.121.issue-s5.
   PubMed Web of Science ®Google Scholar
• Lusti-Narasimhan M, Collins L, Hopkins J. Lessons learnt from sexual and reproductive health and HIV linkages for multipurpose prevention technology service delivery. BJOG: Int J Obstetrics Gynaecol. 2014;121:87–91. doi:10.1111/bjo.2014.121.issue-s5.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Mastroianni AC, Macklin R. Ethical issues for late-stage trials of multipurpose prevention technologies for HIV and pregnancy. Int J Gynaecol Obstet. 2014;127:221–224. doi:10.1016/j.ijgo.2014.07.012.
   PubMed Web of Science ®Google Scholar
• Cleland J, Bernstein S, Ezeh A, et al. Family planning: the unfinished agenda. Lancet. 2006;368:1810–1827. doi:10.1016/S0140-6736(06)69480-4.
   PubMed Web of Science ®Google Scholar
• Cleland J, Shah IH. The contraceptive revolution: focused efforts are still needed. Lancet. 2013;381:1604–1606. doi:10.1016/S0140-6736(13)60588-7.
   PubMed Web of Science ®Google Scholar
• Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360:971–977.
   PubMed Web of Science ®Google Scholar
• Johnson TJ, Clark MR, Albright TH, et al. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother. 2012;56:6272–6283. DOI:10.1128/AAC.01431-12.
   PubMed Web of Science ®Google Scholar
• Clark JT, Clark MR, Shelke NB, et al. Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy. PLoS One. 2014;9:e88509. DOI:10.1371/journal.pone.0088509.
   PubMed Web of Science ®Google Scholar
• Mishell DR Jr. Vaginal contraceptive rings. Ann Med. 1993;25:191–197.
   PubMed Web of Science ®Google Scholar
• Landgren BM, Johannisson E, Masironi B, et al. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate. Contraception. 1982;26:567–585.
   PubMed Web of Science ®Google Scholar
• Burton FG, Skiens WE, Duncan GW. Low-level, progestogen-releasing vaginal contraceptive devices. Contraception. 1979;19:507–516.
   PubMed Web of Science ®Google Scholar
• Burton FG, Skiens WE, Gordon NR, et al. Fabrication and testing of vaginal contraceptive devices designed for release of prespecified dose levels of steroids. Contraception. 1978;17:221–230.
   PubMed Web of Science ®Google Scholar
• Holt J, Derrick T, Brimer A, et al. In vitro design and drug delivery of combination dapivirine and contraceptive hormone ethylene vinyl acetate (EVA) vaginal ring prototypes. AIDS Res Hum Retroviruses. 2014;30:A139–A39. doi:10.1089/aid.2014.5277.abstract.
   Google Scholar
• Malcolm K, McCoy C, Murphy D, et al. Thermal properties and eutectic behaviour of dapivirine in combination with steroid hormones and other antiretrovirals. AIDS Res Hum Retroviruses. 2014;30:A140–A40. doi:10.1089/aid.2014.5279.abstract.
   Web of Science ®Google Scholar
• Malcolm K, Murphy D, McCoy C, et al. Evaluation of the factors contributing to levonorgestrel binding in addition cure silicone elastomer vaginal rings. AIDS Res Hum Retroviruses. 2014;30:A139–A39. doi:10.1089/aid.2014.5278.abstract.
   Google Scholar
• McCoy C, Boyd P, Fetherston S, et al. Development of reservoir vaginal rings containing dapivirine or hormonal contraceptive steroids. AIDS Res Hum Retroviruses. 2014;30:A68–A68. doi:10.1089/aid.2014.5124.abstract.
   Google Scholar
• McCoy C, Boyd P, Fetherston S, et al. Selection of a hormonal contraceptive agent for inclusion with dapivirine in a silicone elastomer vaginal ring. AIDS Res Hum Retroviruses. 2014;30:A140–A40. doi:10.1089/aid.2014.5280.abstract.
   Google Scholar
• Evans AB, Holt J, Nuttall J, et al. Drug-drug interaction studies investigating the impact of Levonorgestrel on antiviral potency of dapivirine. AIDS Res Hum Retroviruses. 2014;30:A137–A37. doi:10.1089/aid.2014.5273.abstract.
   Google Scholar
• Holt J, Brimer A, Fetherston S, et al. Matrix vaginal ring formulations that maintain target in vitro release rates of dapivirine and levonorgestrel (alone or in combination) over 90 days. AIDS Res Hum Retroviruses. 2014;30:A138–A139. doi:10.1089/aid.2014.5276.abstract.
   Google Scholar
• Kizima L, Rodriguez A, Kenney J, et al. A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV. PLoS One. 2014;9:e94547. doi:10.1371/journal.pone.0094547.
   PubMed Web of Science ®Google Scholar
• Ugaonkar SR, Wesenberg A, Wilk J, et al. A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy. J Control Release. 2015;213:57–68. DOI:10.1016/j.jconrel.2015.06.018.
   PubMed Web of Science ®Google Scholar
• Moss JA, Malone AM, Smith TJ, et al. Pharmacokinetics of a multipurpose pod-intravaginal ring simultaneously delivering five drugs in an ovine model. Antimicrob Agents Chemother. 2013;57:3994–3997. DOI:10.1128/AAC.00547-13.
   PubMed Web of Science ®Google Scholar
• Warren M. Condoms: the multipurpose prevention technologies that already exist. BJOG: Int J Obstetrics Gynaecol. 2014;121:9–11. doi:10.1111/1471-0528.12913.
   PubMed Web of Science ®Google Scholar
• Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: a review of the literature. Eur J Contracept Reprod Health Care. 2010;15:4–16. doi:10.3109/13625180903427675.
   PubMed Web of Science ®Google Scholar
• Kramzer LF, Cohen J, Schubert J, et al. Assessing the potential of the Woman’s Condom for vaginal drug delivery. Contraception. 2015;92:254–260. doi:10.1016/j.contraception.2015.05.005.
   PubMed Web of Science ®Google Scholar
• Major I, Boyd P, Kilbourne-Brook M, et al. A modified SILCS contraceptive diaphragm for long-term controlled release of the HIV microbicide dapivirine. Contraception. 2013;88:58–66. doi:10.1016/j.contraception.2012.10.018.
   PubMed Web of Science ®Google Scholar
• Romano JW, Robbiani M, Doncel GF, et al. Non-specific microbicide product development: then and now. Curr HIV Res. 2012;10:9–18.
   PubMed Web of Science ®Google Scholar
• Hicks DR, Martin LS, Getchell JP, et al. Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro. Lancet. 1985;2:1422–1423.
   PubMed Web of Science ®Google Scholar
• Malkovsky M, Newell A, Dalgleish AG. Inactivation of HIV by nonoxynol-9. Lancet. 1988;331:645. doi:10.1016/S0140-6736(88)91440-7.
   Google Scholar
• Asculai SS, Weis MT, Rancourt MW, et al. Inactivation of herpes simplex viruses by nonionic surfactants. Antimicrob Agents Chemother. 1978;13:686–690.
   PubMed Web of Science ®Google Scholar
• Van Damme L, Chandeying V, Ramjee G, et al. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group. AIDS. 2000;14:85–88. COL-1492 Phase II Study Group
   PubMed Web of Science ®Google Scholar
• Vandebosch A, Goetghebeur E, Ramjee G, et al. Acceptability of COL-1492, a vaginal gel, among sex workers in one Asian and three African cities. Sex Transm Infect. 2004;80:241–243.
   PubMed Web of Science ®Google Scholar
• Fichorova RN, Bajpai M, Chandra N, et al. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod. 2004;71:761–769. doi:10.1095/biolreprod.104.029603.
   PubMed Web of Science ®Google Scholar
• Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis. 2001;184:418–428. doi:10.1086/322047.
   PubMed Web of Science ®Google Scholar
• Catalone BJ, Kish-Catalone TM, Budgeon LR, et al. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob Agents Chemother. 2004;48:1837–1847.
   PubMed Web of Science ®Google Scholar
• Zalenskaya IA, Cerocchi OG, Joseph T, et al. Increased COX-2 expression in human vaginal epithelial cells exposed to nonoxynol-9, a vaginal contraceptive microbicide that failed to protect women from HIV-1 infection. Am J Reprod Immunol. 2011;65:569–577. doi:10.1111/j.1600-0897.2010.00964.x.
   PubMed Web of Science ®Google Scholar
• Peterson L, Nanda K, Opoku BK, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One. 2007;2:e1312. doi:10.1371/journal.pone.0001312.
   PubMed Web of Science ®Google Scholar
• Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One. 2008;3:e1474. doi:10.1371/journal.pone.0001474.
   PubMed Web of Science ®Google Scholar
• Burke AE, Barnhart K, Jensen JT, et al. Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial. Obstet Gynecol. 2010;116:1265–1273. doi:10.1097/AOG.0b013e3181fc3b1a.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Feathergill KA, Diao X-H, et al. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J Androl. 2002;23:426–438.
   PubMedGoogle Scholar
• Mauck CK. Noncomparative contraceptive effectiveness trial of cellulose sulfate gel. American College of Obstetricians and Gynecologists’ 54th Annual Clinical Meeting (ACM); 2006; Washington, DC; 2006. p. 14S.
   Google Scholar
• Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359:463–472. doi:10.1056/NEJMoa0707957.
   PubMed Web of Science ®Google Scholar
• Halpern V, Ogunsola F, Obunge O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS One. 2008;3:e3784. doi:10.1371/journal.pone.0003784.
   PubMed Web of Science ®Google Scholar
• Martin LS, Loskoski SL, McDougal JS. Inactivation of human T-lymphotropic virus type III/lymphadenopathy-associated virus by formaldehyde-based reagents. Appl Environ Microbiol. 1987;53:708–709.
   PubMed Web of Science ®Google Scholar
• Ongradi J, Ceccherini-Nelli L, Pistello M, et al. Acid sensitivity of cell-free and cell-associated HIV-1: clinical implications. AIDS Res Hum Retroviruses. 1990;6:1433–1436.
   PubMed Web of Science ®Google Scholar
• Zeitlin L, Hoen TE, Achilles SL, et al. Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis. 2001;28:417–423.
   PubMed Web of Science ®Google Scholar
• Achilles SL, Shete PB, Whaley KJ, et al. Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis. Sex Transm Dis. 2002;29:655–664.
   PubMed Web of Science ®Google Scholar
• Olmsted SS, Dubin NH, Cone RA, et al. The rate at which human sperm are immobilized and killed by mild acidity. Fertil Steril. 2000;73:687–693.
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS, Richardson BA, Ramjee G, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;25:957–966.
   PubMed Web of Science ®Google Scholar
• Bayer LL, Jensen JT. ACIDFORM: a review of the evidence. Contraception. 2014;90:11–18.
   PubMed Web of Science ®Google Scholar
• Garg S, Anderson RA, Chany CJ 2nd, et al. Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). Contraception. 2001;64:67–75.
   PubMed Web of Science ®Google Scholar
• Keller MJ, Carpenter CA, Lo Y, et al. Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive. PLoS One. 2012;7:e46901.
   PubMed Web of Science ®Google Scholar
• Amaral E, Perdigao A, Souza MH, et al. Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDFORM) and a 2% nonoxynol-9 product. Contraception. 2004;70:492–497.
   PubMed Web of Science ®Google Scholar
• Amaral E, Faundes A, Zaneveld L, et al. Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel. Contraception. 1999;60:361–366.
   PubMed Web of Science ®Google Scholar
• Spencer SE, Valentin-Bon IE, Whaley K, et al. Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model. J Infect Dis. 2004;189:410–419.
   PubMed Web of Science ®Google Scholar
• Tuyama AC, Cheshenko N, Carlucci MJ, et al. ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations. J Infect Dis. 2006;194:795–803.
   PubMed Web of Science ®Google Scholar
• Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–1174.
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS, Abdool Karim Q, Kharsany ABM, et al. Tenofovir gel for the prevention of herpes simplex virus type 2 infection. New England J Med. 2015;373:530–539.
   PubMed Web of Science ®Google Scholar
• Andrei G, Lisco A, Vanpouille C, et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe. 2011;10:379–389.
   PubMed Web of Science ®Google Scholar
• Buck CB, Thompson CD, Roberts JN, et al. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2006;2:e69.
   PubMed Web of Science ®Google Scholar
• Kenney J, Singer R, Derby N, et al. A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use. AIDS Res Hum Retroviruses. 2012;28:1476–1484.
   PubMed Web of Science ®Google Scholar
• Kenney J, Aravantinou M, Singer R, et al. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One. 2011;6:e15835.
   PubMedGoogle Scholar
• Fernandez-Romero JA, Abraham CJ, Rodriguez A, et al. Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge. Antimicrob Agents Chemother. 2012;56:358–368.
   PubMed Web of Science ®Google Scholar
• Roberts JN, Kines RC, Katki HA, et al. Effect of pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J Natl Cancer Inst. 2011;103:737–743.
   PubMedGoogle Scholar
• Hendrix CW, Chen BA, Guddera V, et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One. 2013;8:e55013.
   PubMed Web of Science ®Google Scholar
• Louissaint NA, Cao YJ, Skipper PL, et al. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses. 2013;29:1443–1450.
   PubMed Web of Science ®Google Scholar
• The Alan Guttmacher Institute. Unplanned pregnancy common worldwide. [ cited 2015 Sep 22]. Available from: http://www.guttmacher.org/media/nr/abortww_nr.html.
   Google Scholar
• UNICEF data: monitoring the situation of children and women. Maternal mortality: current status and progress. [ cited 2015 Sep 22]. Available from: http://www.data.unicef.org/maternal-health/maternal-mortality.html.
   Google Scholar
• amfAR. Worldwide Statistics [Internet]. [ cited 2015 Sep 22]. Available from: http://www.amfar.org/worldwide-aids-stats/.
   Google Scholar
• Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ. 2008;86:805–12, A.
   PubMed Web of Science ®Google Scholar
• Manning J, Brown G, Vogelsong K, et al. Challenges and opportunities in funding the development and introduction of multipurpose prevention technologies. BJOG: Int J Obstetrics Gynaecol. 2014;121:12–14.
   PubMed Web of Science ®Google Scholar